Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Have any of you thought about making money

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
MedResCollab Member Profile
Followed By 2
Posts 211
Boards Moderated 0
Alias Born 01/18/19
160x600 placeholder
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Pot... GlobeNewswire Inc. - 5/15/2021 8:00:00 AM
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Present... GlobeNewswire Inc. - 5/4/2021 7:00:00 AM
Amarin reports decline in Q1 revenue ahead of European launch of VAZKEPA Seeking Alpha - 4/29/2021 7:31:32 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/29/2021 6:36:55 AM
Amarin EPS beats by $0.07, misses on revenue Seeking Alpha - 4/29/2021 6:16:54 AM
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 4/29/2021 6:10:00 AM
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel GlobeNewswire Inc. - 4/29/2021 6:00:00 AM
Amarin Q1 2021 Earnings Preview Seeking Alpha - 4/28/2021 1:06:54 PM
UK approves Amarin's Vazkepa for cardiovascular risk reduction Seeking Alpha - 4/22/2021 11:22:31 AM
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agenc... GlobeNewswire Inc. - 4/22/2021 10:53:02 AM
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 GlobeNewswire Inc. - 4/20/2021 6:05:00 AM
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Present... GlobeNewswire Inc. - 4/17/2021 9:50:00 AM
Amarin: Could the New CEO Help Vazkepa’s European Push? TipRanks - 4/13/2021 3:05:37 PM
Amarin falls as new CEO may mean M&A less likely in the near term Seeking Alpha - 4/13/2021 8:08:18 AM
Amarin CEO John Thero to retire Seeking Alpha - 4/12/2021 4:36:21 PM
Amarin Announces CEO Succession Plan GlobeNewswire Inc. - 4/12/2021 4:30:00 PM
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular... GlobeNewswire Inc. - 4/6/2021 6:05:00 AM
Amarin wins EU approval for icosapent ethyl to treat cardiovascular patients Seeking Alpha - 3/30/2021 7:42:41 AM
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk GlobeNewswire Inc. - 3/30/2021 6:24:23 AM
Amarin announces clinical recommendations for Vascepa in Canada and Egypt Seeking Alpha - 3/29/2021 10:33:15 AM
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is R... GlobeNewswire Inc. - 3/29/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
HLS Therapeutics highlights promising VASCEPA data analysis Seeking Alpha - 3/17/2021 11:55:39 AM
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in... GlobeNewswire Inc. - 3/17/2021 11:30:00 AM
Amarin Q4 results led by strong Vascepa sales Seeking Alpha - 2/25/2021 9:48:43 AM
MedResCollab   Wednesday, 07/10/19 10:02:24 AM
Re: None
Post # of 339970 
Have any of you thought about making money shorting AMRN? The goal of investing in AMRN is to show a positive ROI, right? You feel that AMRN is an excellent long play, that it will be acquired probably for multiples of its current pps. That is certainly a good basis for a long investment.

But what can happen before the sNDA is approved (if it is)? An AC meeting announcement would most probably cause a sell-off, and an announcement one way or the other is coming soon. We think the behavior of the FDA towards Amarin, as revealed by the CEO at multiple conferences, portends that there will likely be an AC meeting (>80% likely). There is this smaller but ever-present risk that EVAPORATE will be placed on clinical hold, and if that occurs the stock price will fall precipitously, perhaps to <$10. The AC meeting itself could expose unfavorable briefing docs and return an unfavorable result. And/or, within one month to even just before a decision on 9/28 there could be a PR from Amarin that FDA had previously requested information that Amarin submitted and as a result of that submission considered it a major amendment to the sNDA, and thus is extending the PUFA date to Dec 28. There could still be no settlement by mid Dec in patent cases, causing the likelihood of bench trial to be very high (ANDA filers win these overwhelming majority of time).

OR, it's clear sailing to late Sept.

But what is the risk:reward here until late Sept? In our view, the situation Amarin currently finds itself in is extremely skewed to the "risk" side. The market is behaving as if it is 1:5, when it is probably more like 5:1.

Why not only hold puts? And wait until we at least get to mid Sept before deciding to go long again? Let's look at an example:

-Your cost basis in AMRN is $11/share.
-You sell all shares of AMRN at $22, locking in a 100% gain.
-You purchase $14, $15, and $16 strike puts, expiring Jan 2020, with 15% of your above total sold position (15% of basis+profit)

Then two things happen:

-You lose 70% of put value when mid Sept comes and stock is still >$20.
-At this point you still hold those puts as hedge, but go long with the 85% in cash still sitting on the sidelines, losing about 10% overall but avoiding any heavy losses.


-The stock suffers from the above risks coming to fruition, and your put position is currently up 300% -- equivalent to a 45% gain in your long share position.
-You still like your chances despite negative info in briefing docs and negative AdComm vote, so go long your 85% cash sitting on the sidelines, buying at $9 and getting nearly twice the shares you sold from $22. You maintain your put positions as hedge in case PDUFA extended and/or CRL comes.
-OR, because of all of the negative catalysts, increase your put position--OR close it out and lock in 45% gain on top of your already 100% gain.

It doesn't seem logical at all to do anything other than sell all shares and buy puts here. You can always adjust later after the risks pass by.

However, this is not investment advice, and is for informational purposes only; you should seek the advice of a registered investment advisor before doing any of the above.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences